# The Effect of Calcium β-hydroxy-β-methylbutyrate (CaHMB) Supplementation in Sarcopenia in Liver Cirrhosis

> **NCT03605147** · NA · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 120 (estimated)

## Conditions studied

- Sarcopenia
- Cirrhosis, Liver

## Interventions

- **DIETARY_SUPPLEMENT:** CaHMB
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT03605147
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-08-22
- **Primary completion:** 2019-07
- **Final completion:** 2019-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2018-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03605147

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03605147, "The Effect of Calcium β-hydroxy-β-methylbutyrate (CaHMB) Supplementation in Sarcopenia in Liver Cirrhosis". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03605147. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*